Essential Facts for HALO Investors – Stay Informed Today

By Scott Lee • Thursday, August 07 10:04 • Permanent Link

Halozyme Therapeutics logged a 0.0% change during today's morning session, and is now trading at a price of $62.34 per share. The S&P 500 index moved 1.0%. HALO's trading volume is 132,659 compared to the stock's average volume of 2,541,630.

Halozyme Therapeutics trades -10.24% away from its average analyst target price of $69.44 per share. The 9 analysts following the stock have set target prices ranging from $51.0 to $91.0, and on average have given Halozyme Therapeutics a rating of buy.

If you are considering an investment in HALO, you'll want to know the following:

Halozyme Therapeutics's current price is 323.2% above its Graham number of $14.73, which implies that at its current valuation it does not offer a margin of safety
Halozyme Therapeutics has moved 14.4% over the last year, and the S&P 500 logged a change of 19.3%
Based on its trailing earnings per share of 4.37, Halozyme Therapeutics has a trailing 12 month Price to Earnings (P/E) ratio of 14.3 while the S&P 500 average is 29.3
HALO has a forward P/E ratio of 12.9 based on its forward 12 month price to earnings (EPS) of $4.84 per share
Its Price to Book (P/B) ratio is 22.03 compared to its sector average of 3.19
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally.
Based in San Diego, the company has 350 full time employees and a market cap of $7.29 Billion.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.